Cefprozil Dihydrate is a semi-synthetic, broad-spectrum cephalosporin antibiotic that is commonly used in compounded formulations to treat a variety of bacterial infections. It is particularly effective against Gram-positive and some Gram-negative bacteria, making it a versatile choice for healthcare providers managing conditions such as respiratory tract infections, skin infections, and otitis media.

This API works by inhibiting bacterial cell wall synthesis, which ultimately leads to the death of the bacteria. Cefprozil Dihydrate is well-absorbed orally, with a bioavailability of approximately 90%, and it reaches peak plasma concentrations within 1.5 hours after administration. Its half-life is approximately 1.3 hours, allowing for convenient dosing schedules that can enhance patient compliance.

Prescribers should be aware of potential allergic reactions in patients with a history of penicillin allergy, as cross-reactivity may occur. Additionally, while Cefprozil Dihydrate is generally well-tolerated, some patients may experience gastrointestinal disturbances, such as diarrhea or nausea. It is important to consider renal function when dosing, as adjustments may be necessary for patients with renal impairment.

In the context of compounding, Cefprozil Dihydrate offers flexibility in creating tailored formulations that meet specific patient needs, such as liquid suspensions for pediatric or geriatric populations who may have difficulty swallowing tablets. This adaptability makes it a valuable component in personalized medicine, allowing for precise dosing and improved therapeutic outcomes.